Gavilondo J, Pérez R, Mainardi V, Lage A
Neoplasma. 1982;29(3):315-22.
The paper reports on the experiments carried out for the evaluation of the effect of two antiproteinases, aprotinin, and epsilon-amino caproic acid (EACA), on several transplantable tumors and cells in culture. It was demonstrated that aprotinin has a preferential therapeutic effect on the solid form of L1210, in comparison with its ascitic form. Treatment with aprotinin of Lewis lung carcinoma, Melanoma B16, and Hepatoma 22, in a limited chronic time schedule 1-9, and 1-11 brought no significant increase in survival; positive therapeutic effects had been shown for the first and the last of the tumors mentioned with life-time injections of the drug. Moreover, aprotinin treatment increased the number of lung nodules for the Lewis lung carcinoma inoculated either subcutaneously or intravenously. EACA applied same schedule had no effect on the survival of tumor-bearing animals. These data are discussed in terms of their relevance to antiproteinase therapy in human cancer. No selective inhibition of proliferation for more tumorigenic cell culture lines of spontaneous and viral origin was demonstrated after treatment with both compounds.
该论文报道了为评估两种抗蛋白酶(抑肽酶和ε-氨基己酸(EACA))对几种可移植肿瘤及培养细胞的作用而进行的实验。结果表明,与L1210腹水型相比,抑肽酶对其实体型具有优先治疗效果。在有限的慢性时间方案(1 - 9天和1 - 11天)下,用抑肽酶治疗Lewis肺癌、黑色素瘤B16和肝癌22,并未使存活率显著提高;对上述第一种和最后一种肿瘤进行药物终身注射已显示出积极的治疗效果。此外,抑肽酶治疗增加了皮下或静脉接种Lewis肺癌的肺结节数量。采用相同方案应用EACA对荷瘤动物的存活率没有影响。根据这些数据与人类癌症抗蛋白酶治疗的相关性进行了讨论。用这两种化合物处理后,未显示对更多自发和病毒起源的致瘤性细胞系的增殖有选择性抑制作用。